Drug Showed 90 Percent Kill Of Leukemic Stem Cells And Prolonged Survival In Mice With Resistant CML
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) has announced. The findings of this study provide new insights into the problem of minimal residual disease and may open the door to the development of a curative treatment strategy for some patients with CML.
[Read the full article here]Related News:
Survival Prolonged In Mouse Model Of Rare Brain Disease By Transplanted Human Stem Cells
Marshall Edwards Announces Publication Of Pre-Clinical Study Showing Activity In Chemotherapy-Resistant Ovarian Cancer Stem Cells
Stubborn Leukemia Stem Cells Targeted By Combination Therapy